Mumbai,
Total revenues for the 9 month
period this fiscal year were $51,195,666 which is well on pace to meet or
exceed the previously announced 12 month guidance. Net earnings for the same
period were $5,132,140, just shy of .11 per share.
Cash reserves in the form of short term
investments and deposits are extremely healthy and the Company?s backlog of
orders is larger than ever and growing while long term debt remains virtually
non-existent.
The Indian pharmaceutical
industry is increasingly focusing on exports to the
The company also continues to
negotiate with several Indian drug companies for the manufacture of generic
pharmaceuticals that the company intends to market in the
About Groupe Athena, Inc.
Groupe
Athena, Inc. was incorporated in June 2008 and
began operations on July 1 of
that year. The company is a research and testing organization and helps various
pharmaceutical and medical products and devices companies in
The company has a research and
marketing facility in
To review the complete
quarterly report please go to www.otcmarkets.com/stock/GATA/quote and
click on ?Financials?
For more information contact:
Paul Cornell
Cornellpaul6@gmail.com
Certain statements set forth in this press
release constitute "forward-looking statements.? Forward-looking
statements include, without limitation, any statement that may predict,
forecast, indicate, or imply future results, performance or achievements, and
may contain the words "estimate", "project",
"intend", "forecast", "anticipate",
"plan", "planning", "expect",
"believe", "will likely", "should",
"could", "would", "may" or words or expressions
of similar meaning. Such statements are not guarantees of future performance
and are subject to risks and uncertainties that could cause the company's
actual results and financial position to differ materially from those included
within the forward-looking statements. Forward-looking statements involve risks
and uncertainties, including those relating to the Company's ability to grow
its business. Actual results may differ materially from the results predicted
and reported results should not be considered as an indication of future
performance. The potential risks and uncertainties include, among others, the
Company's limited operating history, the limited financial resources, domestic
or global economic conditions -- activities of competitors and the presence of
new or additional competition and conditions of equity markets.